Trial Profile
Phase II/III study of TS-1+irinotecan+cetuximab as the first-line therapy in patients with KRAS wild-type metastatic colorectal cancer
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 05 Aug 2015
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 05 Aug 2015 New trial record